Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Reset IV, LLC dba Reset IV
WARNING LETTER
•Reset IV, LLC dba Reset IV•August 31, 2025

Reset IV, LLC dba Reset IV – FDA Warning Letter, Aug 31, 2025

Record Details

The FDA issued a warning letter to Reset IV on September 9, 2025, following an inspection of their website in August 2025. The inspection revealed that Reset IV was offering compounded drug products, specifically semaglutide and tirzepatide, with claims that were deemed false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA). These claims suggested that the compounded products were equivalent to FDA-approved drugs, which they are not, resulting in the products being classified as misbranded.

The regulatory framework cited includes sections 502(a), 502(bb), and 301(a) of the FDCA, which prohibit the introduction of misbranded drugs into interstate commerce. The FDA emphasized that the violations noted are not exhaustive, and Reset IV is responsible for ensuring compliance with all federal laws and FDA regulations.

The FDA requires Reset IV to take immediate corrective actions, such as ceasing the misleading claims. The company must respond in writing within 15 working days, detailing the steps taken to address the violations and prevent recurrence. Failure to comply may result in legal actions, including seizure and injunction. Reset IV is also advised that if their products are not in violation, they should provide supporting information for consideration. Correspondence should be directed to the Office of Compounding Quality and Compliance.

Company
Reset IV, LLC dba Reset IV
Inspection date
August 31, 2025
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • George Tidmarsh (Director)
View Company Profile

ID · 229132dd-e5af-47da-b311-d6111b14a3b7

Violation Codes10
21 U.S.C. 321(g)21 U.S.C. 352(a)FD&C Act 301(c)FD&C Act 201(p)21 U.S.C. 352(bb)21 U.S.C. 331(c)21 U.S.C. 321(p)FD&C Act 502(a)FD&C Act 301(a)FD&C Act 201(g)

Full citation text and observation details available on the Dashboard.

Other documents for Reset IV, LLC dba Reset IV
  • WARNING_LETTER - 2025-08-01August 1, 2025

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Reset IV, LLC dba Reset IV
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.